Clinic Roundup

Onyx Pharmaceuticals Inc., of Emeryville, Calif., reported updated results from the Phase IIb 003-A1 study of single-agent carfilzomib for treatment of patients with relapsed and refractory multiple myeloma in which carfilzomib achieved a clinical benefit rate (minimal response or greater) in the study population of 37 percent with a duration of response of 8.3 months. The primary endpoint, overall response rate (defined as partial response or greater) was 24 percent with a median duration of response of 7.8 months.